Valuation: Bicycle Therapeutics plc

Market Cap 269M 237M 221M 203M 380M 25.81B 389M 2.62B 1.02B 12.77B 1.01B 990M 44.15B P/E 2026 *
-1.62x
P/E 2027 * -1.78x
Enterprise Value -243M -213M -199M -183M -342M -23.23B -350M -2.36B -922M -11.49B -911M -891M -39.74B EV / Sales 2026 *
-14.2x
EV / Sales 2027 * -8.68x
Free-Float
6.21%
Yield 2026 *
-
Yield 2027 * -
1 day+1.94%
1 week-6.13%
Current month-7.90%
1 month-7.90%
3 months-17.27%
6 months-39.17%
Current year-44.84%
1 week 3.81
Extreme 3.81
4.16
1 month 3.81
Extreme 3.81
4.52
Current year 3.81
Extreme 3.81
7.34
1 year 3.81
Extreme 3.81
9.16
3 years 3.81
Extreme 3.81
28.67
5 years 3.81
Extreme 3.81
62.08
10 years 3.81
Extreme 3.81
62.08
Manager TitleAgeSince
Chief Executive Officer 57 01/09/2015
Director of Finance/CFO 46 29/01/2026
Chief Tech/Sci/R&D Officer - 01/06/2025
Director TitleAgeSince
Director/Board Member 57 01/09/2015
Director/Board Member 63 17/03/2021
Director/Board Member 69 20/02/2024
Date Insider Type Main position Quantity % Market Cap.
15/7/26 Free

CHIEF PROD & SUPPLY CHAIN OFF

60,000 0.1580%
15/7/26 Free

Chief Technology Officer

60,000 0.1580%
15/7/26 Free

Chief Operating Officer

60,000 0.1580%
Change 5-day change 1-year change 3-year change Capi.($)
+2.33%-6.13%-54.11%-84.13% 269M
-3.74%-6.32%+42.70%+63.37% 55.2B
-0.81%-0.33%+27.15%+81.12% 55.6B
-0.60%+0.22%-16.17%-15.26% 23.51B
-3.04%-6.70%-4.73%+353.64% 22.35B
-4.01%-2.68%+12.50%-12.70% 20.6B
-1.23%-3.15%+26.00%-33.84% 17.45B
-3.34%-6.96%+22.02%+515.48% 15.16B
-0.04%-1.01%+49.48%+179.50% 13.91B
-5.09%-13.14%+151.85%+272.20% 13.74B
Average -2.07%-2.22%+25.67%+131.94% 23.78B
Weighted average by Cap. -2.40%-0.47%+30.22%+120.83%

Financials

2026 *2027 *
Net sales 17.08M 15.01M 14.01M 12.86M 24.07M 1.64B 24.67M 166M 64.98M 810M 64.14M 62.75M 2.8B 15.52M 13.64M 12.73M 11.69M 21.87M 1.49B 22.41M 151M 59.05M 736M 58.28M 57.02M 2.54B
Net income -159M -139M -130M -119M -224M -15.2B -229M -1.54B -603M -7.52B -596M -583M -25.99B -164M -144M -134M -123M -230M -15.66B -236M -1.59B -622M -7.75B -614M -601M -26.79B
Net Debt -512M -450M -420M -385M -721M -49.04B -739M -4.98B -1.95B -24.27B -1.92B -1.88B -83.89B -404M -355M -331M -304M -569M -38.71B -584M -3.93B -1.54B -19.16B -1.52B -1.48B -66.22B
Logo Bicycle Therapeutics plc
Bicycle Therapeutics plc is a United Kingdom-based clinical-stage biopharmaceutical company developing a class of medicines, referred to as Bicycle molecules, for diseases that are underserved by existing therapeutics. Bicycle molecules are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. The Company is evaluating zelenectide pevedotin, a Bicycle Toxin Conjugate (BTC) targeting Nectin-4, a well-validated tumor antigen; BT5528, a BTC targeting EphA2, a historically undruggable target, and BT7480, a Bicycle Tumor-Targeted Immune Cell Agonist (Bicycle TICA) targeting Nectin-4 and agonizing CD137, in Company-sponsored clinical trials. Additionally, the Company is developing Bicycle Radio Conjugates (BRC) for radiopharmaceutical use and, through various partnerships, is exploring the use of Bicycle technology to develop therapies for diseases beyond oncology.
Employees
288
Date Price Change Volume
31/07/26 USD 3.910 +1.30% 96,459
29/07/26 USD 3.860 -2.03% 352,219
28/07/26 USD 3.940 -0.25% 320,853
27/07/26 USD 3.950 +2.07% 303,823
24/07/26 USD 3.870 -6.97% 572,862
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
9
Last Close Price
3.860USD
Average target price
13.57USD
Spread / Average Target
+251.59%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. BCYC Stock